FDA 483 OBSERVATION · #58 OF 1,923 MOST-CITED
Written procedures - quality control operations
FDA cited this observation 434 times across 371 firms in recent inspections. Below: how it breaks down by program area and fiscal year, and real examples of how FDA worded it on Form FDA 483.
What this grouping is not
An observation-type page groups FDA’s published citation records. The grouping, the compliance steps and the root causes are SPEQ synthesis, not an FDA classification of any citation, and a count measures what FDA published rather than risk.
What this observation means, and how to comply
SPEQ's practitioner reading of this finding. The regulatory basis is a cited fact; the interpretation, compliance steps, and root causes are SPEQ synthesis — not an FDA classification of the citation.
The responsibilities and procedures of the quality control unit were not in writing, or were not followed — including the unit’s authority to approve or reject components, in-process materials, and finished products, and to review records.
Why FDA writes it — The quality control unit is the independent gate on product release. If its responsibilities and procedures are not written and followed, its authority is undefined, and release decisions cannot be shown to be independent and controlled — which is why FDA treats the QC-unit foundation as a first-order requirement.
- Establish in writing the responsibilities and procedures applicable to the quality control unit, including its authority to approve or reject all components, containers, in-process materials, packaging, labeling, and finished products.
- Give the QC unit adequate authority and independence to carry out its responsibilities, and ensure procedures are followed.
- Provide the QC unit adequate laboratory facilities for testing and approval (or rejection) of materials and products.
- Ensure the unit reviews production and control records before release.
- The QC unit’s authority is exercised in practice but never formalised in written procedures, so independence cannot be demonstrated.
- Production pressure erodes the unit’s independence, and no written procedure protects the release gate.
How to close this finding — and stop it recurring
What this observation is associated with
Firms cited for this observation also appear in FDA compliance actions — warning letters, injunctions, or seizures — at 4.1× the rate of the average FDA-cited firm (31.5% vs 7.8%), across 371 FEI-matched firms.
This is an association, not causation, and reflects co-occurrence in FDA's records — not a claim that the observation caused or preceded the action.
How FDA worded it — real examples
You did not follow written procedures for quality control operations.
You did not follow written procedures for quality control operations.
You did not follow written procedures for quality control operations.
You did not establish written procedures for quality control operations.
You did not follow written procedures for quality control operations.
You did not establish written procedures for quality control operations.
Related SPEQ references
Where to read the requirements behind this observation area on SPEQ. These are SPEQ's topic and audience pages — not an FDA classification of the citation.
Examples are a representative sample of FDA's published inspection observations. Open the 483 observation explorer →